Zhengzhou Chiral Pharmaceutical Research Institute Co., Ltd. is a professional manufacturer of novel pharmaceuticals, pesticides, and their intermediates. The company focuses on chiral drugs as its primary research direction, driven by market demands in areas such as new drug intermediates, pharmaceutical excipients, and novel drug formulations. It tracks international advancements in pharmaceutical technology, conducts applied research, promotes industry-academia collaboration, and accelerates the commercialization of new drugs.

Since its establishment, the company has adhered to the business philosophy that "rock-solid credibility and high-quality service are the foundation of the enterprise." It diligently enhances technological innovation capabilities, continuously improves product quality, and strives to provide excellent after-sales service. The company has been honored with titles such as National High-Tech Enterprise, Zhengzhou New R&D Institution, Henan Provincial Engineering Technology Center, Zhengzhou Specialized and Sophisticated SME, and Zhengzhou Scale Enterprise. Upholding the values of "green, health, struggle, and sharing," and embracing the entrepreneurial vision of "contributing to human health by creating first-class pharmaceuticals," the company is committed to providing high-quality and affordable chemical services for new drug development. Its vision is to build an efficient and high-quality platform for the industrialization of new drugs. Following an international and professional management model, the company emphasizes a people-oriented approach and collaborates with domestic and international peers to contribute to global drug development efforts.

Currently, the company has established a 2,500-square-meter R&D center in Zhongyuan Zhigu, Xingyang City, Zhengzhou. It is equipped with multiple high-precision pharmaceutical analysis instruments and advanced drug development equipment, including NMR (Nuclear Magnetic Resonance Spectrometer), LC-MS-MS (Ultra-High Performance Liquid Chromatography-Mass Spectrometer), HPLC (High-Performance Liquid Chromatography), and GC (Gas Chromatography). The company places great emphasis on the recruitment and cultivation of high-end pharmaceutical R&D talent. It currently employs 36 R&D personnel, including 6 Ph.D. holders and 18 master's degree holders, accounting for 80% of the total workforce. Key staff members possess over 10 years of research and production experience. Leveraging a team of theoretically grounded and experienced drug development professionals and advanced high-precision instruments, the company provides clients with efficient services in molecular design, process optimization, quality research, and engineering for new drug development.

Moving forward, Zhengzhou Chiral Pharmaceutical Research Institute will continue to be market-oriented, relying on its strong drug development capabilities. Adhering to the business philosophy of "providing efficient new drug development services with rock-solid credibility," the company aims to create value for clients, benefit employees, and contribute to the advancement of pharmaceutical science.